Payment overview · 2025
General Payments
$1,627.69
92 reported records · 24 companies
Healthcare provider profile · identity verified
Amanda Turner, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ST GEORGE, UT · NPI 1720216021
Verified facts
What the public records show
CMS Open Payments records show Amanda Turner, FNP received $1,627.69 in general payments during 2025 across 92 reported records.
ABBVIE INC. accounted for 24.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Paxlovid, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $391.26 | 24.0% | 27 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $159.22 | 9.8% | 9 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $136.83 | 8.4% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $97.48 | 6.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $90.99 | 5.6% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $85.29 | 5.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.98 | 4.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.81 | 4.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $55.77 | 3.4% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $55.23 | 3.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $49.45 | 3.0% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $45.17 | 2.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.41 | 2.4% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $36.46 | 2.2% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $36.40 | 2.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.45 | 2.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.50 | 2.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $27.18 | 1.7% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $23.69 | 1.5% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $21.88 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.39 | 1.2% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $19.32 | 1.2% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $17.28 | 1.1% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $17.25 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,627.69 | 92 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $257.98 | 16 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $238.82 | 15 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $136.83 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $123.49 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $103.47 | 9 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $82.55 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $82.55 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $69.66 | 3 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $69.31 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $68.14 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $60.11 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $55.77 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $55.23 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $49.45 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $45.17 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $40.81 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.41 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.29 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $37.04 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $36.46 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $36.40 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.82 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $27.52 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $27.18 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 94 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 20 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 490 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 460 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 315 | 93 |
| Lisinopril | Lisinopril | 270 | 74 |
| Omeprazole | Omeprazole | 269 | 75 |
| Losartan Potassium | Losartan Potassium | 264 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 70 |
| Trazodone Hcl | Trazodone Hcl | 200 | 55 |
| Gabapentin | Gabapentin | 172 | 51 |
| Fluoxetine Hcl | Fluoxetine Hcl | 163 | 48 |
| Metformin Hcl | Metformin Hcl | 161 | 52 |
| Alprazolam | Alprazolam | 160 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 157 | 30 |
| Bupropion Xl | Bupropion Hcl | 124 | 31 |
| Simvastatin | Simvastatin | 123 | 31 |
| Celecoxib | Celecoxib | 111 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 24 |
| Potassium Chloride | Potassium Chloride | 107 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 106 | 31 |
| Furosemide | Furosemide | 106 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 103 | 20 |
| Meloxicam | Meloxicam | 100 | 42 |
| Jardiance | Empagliflozin | 94 | 22 |
| Montelukast Sodium | Montelukast Sodium | 93 | 22 |
| Lorazepam | Lorazepam | 92 | 20 |
| Alendronate Sodium | Alendronate Sodium | 91 | 24 |
| Tramadol Hcl | Tramadol Hcl | 91 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 24 |
| Temazepam | Temazepam | 85 | 13 |
| Azithromycin | Azithromycin | 84 | 74 |
| Estradiol | Estradiol | 84 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 25 |
| Sertraline Hcl | Sertraline Hcl | 77 | 26 |
| Allopurinol | Allopurinol | 76 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 71 | 58 |
| Ozempic | Semaglutide | 70 | 17 |
| Cephalexin | Cephalexin | 68 | 47 |
| Eliquis | Apixaban | 66 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 31 |
| Famotidine | Famotidine | 63 | 22 |
| Clonazepam | Clonazepam | 59 | suppressed |
| Diazepam | Diazepam | 58 | 15 |
| Prednisone | Prednisone | 55 | 47 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 12 |
| Spironolactone | Spironolactone | 53 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 19 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 18 |
| Fluconazole | Fluconazole | 48 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 33 |
| Atenolol | Atenolol | 46 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 41 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Ezetimibe | Ezetimibe | 38 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 31 |
| Methenamine Hippurate | Methenamine Hippurate | 37 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 14 |
| Propranolol Hcl | Propranolol Hcl | 37 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Carvedilol | Carvedilol | 35 | suppressed |
| Glipizide Er | Glipizide | 34 | 14 |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Progesterone | Progesterone, Micronized | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 21 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 16 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 11 |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 25 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | 13 |
| Methylprednisolone | Methylprednisolone | 25 | 23 |
| Nystatin | Nystatin | 25 | 11 |
| Baclofen | Baclofen | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Synjardy | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Np Thyroid | Thyroid,pork | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Perphenazine | Perphenazine | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Topiramate Er | Topiramate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,627.69 · 92 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AUSTEDO XR, BEYFORTUS, CAPLYTA, COMIRNATY, CRYSVITA, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, General - Pain Management, JARDIANCE, KISUNLA, KRYSTEXXA, Kerendia, LEQVIO, MOUNJARO, NEXPLANON, NP Thyroid 60, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, QULIPTA, Quviviq, REXULTI, REZDIFFRA, TRINTELLIX, TZIELD, UBRELVY, VRAYLAR, WATCHMAN FLX, XYOSTED, ZENPEP, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error